[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100473423":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":85,"collaborators":26,"id":88,"slug":89,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":90,"sex":96,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":26,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":26,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"University of Oulu","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Prednisolone","EXPERIMENTAL","Prednisolone Sodium Phosphate (25 mg\u002F5 mL) oral suspension administered 1 mg\u002Fkg\\* (up to 20 mg = 4 mL) once a day for 3 days.\n\n\\*(0-5 kg: 5 mg; 5.01-7.5 kg: 7.5 mg; 7.51-10 kg: 10 mg; 10.01-12.5 kg: 12.5 mg; 12.51-15 kg: 15 mg; 15.01-17.5 kg: 17.5 mg; ≥ 17.51 kg: 20 mg)",[13],"Drug: Prednisolone Sodium Phosphate",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Sugar syrup oral suspension containing saccharum 630-640 mg\u002Fg and aqua purificata 360-370 mg\u002Fg administered the same amount in milliliters as experimental product (up to 4 mL) once a day for 3 days.",[19],"Drug: Sugar syrup",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Prednisolone Sodium Phosphate","Oral suspension administered 1 mg\u002Fkg once a day for three days",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Sugar syrup","Oral suspension administered the same amount in milliliters as experimental product once a day for three days",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Ville Lindholm, MD","CONTACT","+35883155283","Ville.a.lindholm@oulu.fi",[38,54],{"facility":39,"status":40,"city":41,"state":26,"zip":26,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"SOITE Lastenpäivystys","RECRUITING","Kokkola","Finland","FI",{"type":45,"coordinates":46},"Point",[47,48],23.13066,63.83847,{"lat":48,"lon":47},[51],{"name":52,"role":34,"phone":26,"phoneExt":26,"email":53},"Nelli Korpela, M.D., PhD","nelli.korpela@oulu.fi",{"facility":55,"status":40,"city":56,"state":26,"zip":57,"country":42,"countryCode":43,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"OYS Lastenpäivystys","Oulu","90130",{"type":45,"coordinates":59},[60,61],25.46816,65.01236,{"lat":61,"lon":60},[64,65,69,71,73,75,77,79,81,83],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"name":66,"role":34,"phone":67,"phoneExt":26,"email":68},"Terhi Tapiainen, MD, PhD","+358-8-315 5185","terhi.tapiainen@oulu.fi",{"name":66,"role":70,"phone":26,"phoneExt":26,"email":26},"PRINCIPAL_INVESTIGATOR",{"name":33,"role":72,"phone":26,"phoneExt":26,"email":26},"SUB_INVESTIGATOR",{"name":74,"role":72,"phone":26,"phoneExt":26,"email":26},"Minna Honkila, MD, PhD",{"name":76,"role":72,"phone":26,"phoneExt":26,"email":26},"Kimmo Halt, MD",{"name":78,"role":72,"phone":26,"phoneExt":26,"email":26},"Tytti Pokka, MSc",{"name":80,"role":72,"phone":26,"phoneExt":26,"email":26},"Ulla Koskela, MD, PhD",{"name":82,"role":72,"phone":26,"phoneExt":26,"email":26},"Niko Paalanne, MD, PhD",{"name":84,"role":72,"phone":26,"phoneExt":26,"email":26},"Tuomas Jartti, MD, PhD",{"type":70,"investigatorFullName":86,"investigatorTitle":87,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Terhi Tapiainen","Professor of Pediatrics, Head of Pediatric Infectious Diseases and Emergency Department","100473423","phase-4-oral-prednisolone-for-acute-rhinovirus-induced-wheezing-in-children-less-than-2-years-of-age-100473423",false,"NCT05444699","Oral Prednisolone for Acute Rhinovirus Induced Wheezing in Children Less Than 2 Years of Age","Oral Prednisolone for Acute Rhinovirus Induced Wheezing in Children Less Than 2 Years of Age: a Point-of-care Testing Guided Randomized, Double-blind, Placebo-controlled Trial","RhinoPOCRCT","Inclusion Criteria:\n\n* Wheezing bronchitis diagnosed by a physician\n* Need for salbutamol treatment at the emergency department\n* Positive nasopharyngeal rhinovirus or picornavirus finding in point-of-care testing\n\nExclusion Criteria:\n\n* Need for immediate resuscitation\n* Immediate transfer to ICU\n* Suspected pneumonia based on the auscultation finding\n* Suspected serious bacterial infection\n* Other respiratory virus finding in the absence of rhinovirus or picornavirus\n* Positive respiratory syncytial virus finding\n* Positive SARS-coronavirus-2 finding\n* Positive Mycoplasma pneumoniae finding\n* Positive Bordetella pertussis finding\n* Contact with a person with chickenpox within 14 days\n* Active chickenpox\n* Suspected foreign body of the respiratory tract\n* Immunosuppressive treatment\n* Systemic corticosteroid treatment within 14 days\n* Allergy to corticosteroids","ALL","6 Months","24 Months",{"count":100,"type":101},210,"ESTIMATED","INTERVENTIONAL",[104],"PHASE4","The aim of the trial is to evaluate whether the use of oral prednisolone directed by point-of-care testing is useful in acute wheezing caused by rhinovirus in children aged 6-24 months.",[107],"Bronchiolitis Acute Viral","2025-02-11",{"date":110,"type":111},"2025-02-13","ACTUAL",{"date":113,"type":111},"2022-10-11",{"date":115,"type":101},"2027-09",{"name":5,"class":6},2]